

SKYEPHARMA PLC  
Form S-8 POS  
June 04, 2007

Registration Nos. 333-10006  
333-14232

---

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

---

**POST-EFFECTIVE AMENDMENT NO. 1 TO**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE  
SECURITIES ACT OF 1933**

---

**SkyePharma PLC**

(Exact Name of Registrant as Specified in Its Charter)

**England and Wales**

(State or Other Jurisdiction of  
Incorporation or Organization)

**330387911**

(IRS Employer  
Identification Number)

**105 Piccadilly**

**London, W1J 7NJ**

**England**

Tel: +44 (0)20 7491-1777

(Address, including zip code, and telephone number, including  
area code, of registrant's principal executive offices)

---

**European and North American Executive Share Option Scheme**

**SkyePharma PLC 2002 Employee Stock Purchase Plan**

**International Share Plan**

(Full Title of the Plans)

---

Donald Puglisi

Puglisi & Associates

850 Library Avenue, Suite 204

Newark, Delaware 19711

(Name, address, including zip code, and telephone number,  
including area code, of agent for service)

---

Copy of Communications to:

Kathryn A. Campbell  
Sullivan & Cromwell LLP  
1 New Fetter Lane  
London, EC4 1AN  
England

---

**EXPLANATORY NOTE/DEREGISTRATION OF UNSOLD SECURITIES**

This post-effective amendment relates to the following Registration Statements filed on Form S-8 (collectively, the Registration Statements ):

1. Registration Statement 333-10006, filed February 12, 1999, registering 5,000,000 ordinary shares of 10 pence each under the above-referenced European and North American Executive Share Option Scheme; and
2. Registration Statement 333-14232, filed December 27, 2001, registering 10,000,000 ordinary shares of 10 pence each for the SkyePharma 2002 Employee Purchase Plan and International Plan.

In accordance with an undertaking made by SkyePharma in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, SkyePharma hereby removes from registration the securities registered but unsold under the Registration Statements.

-2-

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunder duly authorized, in the city of London, England on June 4, 2007.

SkyePharma PLC

By: /s/ Frank Condella  
Name: Frank Condella  
Title: Chief Executive Officer

-3-

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment has been signed by or on behalf of the following persons in the capacities indicated as of June 4, 2007:

/s/ Dr Ken Cunningham  
Name: Dr Ken Cunningham  
Chief Operating Officer

/s/ Donald Puglisi  
Name: Donald Puglisi  
Puglisi & Associates  
Authorized U.S. Representative

Edgar Filing: SKYEPHARMA PLC - Form S-8 POS

---

Name: Dr Argeris Karabelas  
Non-Executive Chairman  
Officer

---

/s/ Peter Grant  
Name: Peter Grant  
Principal Accounting & Financial  
Officer

---

/s/ Stephen Harris  
Name: Stephen Harris  
Non-Executive Director

---

/s/ Frank Condella  
Name: Frank Condella  
Chief Executive Officer  
Principal Executive Officer

---

Name: David Ebsworth  
Non-Executive Director

---

Name: Alan Bray  
Non-executive Director / Chairman  
of Audit Committee

-4-